The influence of statin characteristics on their safety and tolerability

International Journal of Clinical Practice

Volumn 58, Issue 10, 2004, Pages 945-955

  De Angelis, Giuseppe ^a  

^a RHO HOSPITAL   (Italy)

Author keywords

Adverse effects; Drug interactions; HMG CoA reductase inhibitors; Hypercholesterolaemia

Indexed keywords

ALPRENOLOL; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450; DICLOFENAC; DIGOXIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HEXOBARBITAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NICOTINIC ACID; OMEPRAZOLE; PARACETAMOL; PHENACETIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DISEASE; MUSCLE DISEASE; MYALGIA; NEUROLOGIC DISEASE; OXIDATION; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SLEEP DISORDER; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RHABDOMYOLYSIS;

EID: 10444237960     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00355.x     Document Type: Review

References (92)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002; 89: 50C-57C.
3. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003; 17: 265-85.
4. Serruys PWJC, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 287: 3215-22.
5. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
6. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
7. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360: 1623-30.
8. Pedersen TR, Kjekshus J, Pyörälä K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998; 81: 333-5.
9. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
10. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305-10.
11. Hebert PR, Gaziano, JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-21.
12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
13. Fruchart JC, Duriez P. HDL and triglycerides as therapeutic targets. Curr Opin Lipidol 2002; 13: 605-16.
14. Downs JR, Clearfield M, Weiss S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: result of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
15. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285: 1585-91.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
17. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24 1601-10.
18. Herd JA, Ballantyne CM, Farmer JA et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86.
19. Bellosta S, Bernini F, Quarato P et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 (Suppl.): S101-9.
20. Bernini F, Didoni G, Bonfadini G et al. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993; 104: 19-26.
21. Corsini A, Mazzotti M, Raiteri M et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117-25.
22. SoRelle R. Baycol withdrawn from market. Circulation 2001; 104: E9015-6.
23. Bellosta S, Ferri N, Bernini F et al. Non-lipid-related effects of statins. Ann Med 2000; 32: 164-76.
24. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
25. Mason JC. Statins and their role in vascular protection. Clin Sci (Lond) 2003; 105: 251-66.
26. Bellosta S, Ferri N, Arnaboldi L et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23 (Suppl. 2): B72-8.
27. Comparato C, Altana C, Bellosta S et al. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001; 11: 328-43.
28. Ridker PM, Rifai N, Pfeffer MA et al. For the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
29. Cheng-Lai A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis 2003; 5: 72-8.
30. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.
31. Garcia MJ, Reinoso RF, Sanchez Navarro A et al. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003; 25: 457-81.
32. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-8.
33. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler Suppl 2002; 2: 33-6 (Discussion 36-7).
34. Wang E, Casciano CN, Clement RP et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001; 18: 800-6.
35. Reinoso RF, Sanchez Navarro A, Garcia MJ et al. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2002; 24: 593-613.
36. Brinton EA. Newer HMG CoA reductase inhibitor (statin) therapies. Clin Cardiol 2001; 24 (Suppl.): 10-3.
37. Appel-Dingemanse S, Sabia H, Prasad P et al. Pharmacokinetics, safety, and tolerability of three extended-release formulations of fluvastatin in healthy subjects. 29th European Symposium on Clinical Pharmacy, October 11-14, 2000, Basel, Switzerland. (Abstract 47).
38. Corsini A, Bellosta S, Baetta R et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
39. Simonson SG, Martin PD, Mitchell P et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003; 58: 669-75.
40. Curran MP, Goa KL. Lovastatin extended release: a review of its use in the management of hypercholesterolaemia. Drugs 2003; 63: 685-99.
41. Kitazawa E, Tamura N, Iwabuchi H et al. Biotransformation of pravastatin sodium. (1). Mechanisms of enzymatic transformation and epimerization of an allelic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993; 192: 597-602.
42. Cheng H, Rogers JD, Sweany AE et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992; 9: 1629-33.
43. Appel S, Dingemanse J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 1996; 32: 39-55.
44. Fujino H, Yamada I, Shimada S et al. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002; 52: 745-53.
45. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-58.
46. Gibaldi M. Pharmacokinetic variability-drug interactions. In: Gibaldi M, ed. Biopharmaceutics and Clinical Pharmacokinetics, 4th edn. Philadelphia: Lea & Febiger, 1991:305-43.
47. Thummel KE, Wilkinson GR. In vitro and in vivo drug interaction involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430.
48. Ballantyne CM, Corsini A, Davidson MH et al. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64.
49. Corpier CL, Jones PH, Suki WN et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41.
50. Garnett WR. Interactions with hydroxymethlglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52: 1639-45.
51. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367-78.
52. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of P450 3A and p-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995: 13: 129-34.
53. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39: 1203-11.
54. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.
55. Boyd RA, Stern RH, Stewart BH et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8.
56. Bogman K, Peyer AK, Torok M et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132: 1183-92.
57. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17 209-15.
58. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med 2000; 160 2273-80.
59. Dujovne CA, Chremos AN, Pool JL et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91 (Suppl. 1B): 25-30S.
60. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-85.
61. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 1996; 1: 11-24.
62. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743-59.
63. Steiner A, Weisser B, Vetter W. A comparative review of the adverse effects of treatments for hyperlipidaemia. Drug Saf 1991; 6: 118-30.
64. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzime A reductase. Am J Cardiol 1994; 73: 3-11D.
65. Ziegler O, Drouin P. Safety, tolerability, and efficacy of simvastatin and fenofibrate a multicenter study. Simvastatin-Fenofibrate Study Group. Cardiology 1990; 77 (Suppl. 4): 50-7.
66. Dujovne CA. Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis". Am J Cardiol 2002; 89: 1411-3.
67. Herman RJ. Drug interactions and the statins. Can Med Assoc J 1999; 161: 1281-6.
68. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
69. Berland Y, Vacher Coponat H, Durand C et al. Rhabdomyolysis with simvastatin use. Nephron 1991; 57: 365-6.
70. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19: 355-71.
71. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-17.
72. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.
73. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40.
74. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95.
75. East C, Alivizatos PA, Grundy SM et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-8.
76. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368-9.
77. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999; 83: 1146.
78. Wierzbicki AS, Mikhailidis DP, Wray R et al. Statin and fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003; 19: 155-68.
79. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South med J 1997; 90: 546-7.
80. Spence JD, Munoz CE, Hendicks L et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80-3A.
81. Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003; 163: 2394-5.
82. Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-12.
83. Backman JT, Kyrklund C, Kivisto KT et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9.
84. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340-5.
85. Prueksaritanont T, Zhao JJ, Ma B et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-51.
86. Prueksaritanont T, Tang C, Qiu Y et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280-7.
87. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm 2003; 60: 698-700.
88. Roten L, Schoenenberger RA, Krahenbuhl S et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38: 978-81.
89. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4: 117-38.
90. Martin PD, Warwick MJ, Dane AL et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003; 25: 2553-63.
91. Dujovne CA. New lipid lowering drugs and new effects of old drugs. Curr Opin Lipidol 1997; 8: 362-8.
92. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis 2002; 3 (Suppl.): 35-40.